GRAL Earnings

GRAL reported its earnings on 2026-02-19, showcasing a revenue of 43.60M against an estimate of 43.48M, resulting in a 0.28% surprise. The EPS was -2.44, surpassing the expected -3.33 by 26.73%. The stock experienced a -50.55% price change on the earnings day and a -48.99% change over the next five days, reflecting market reactions to the results.

Following GRAL's earnings announcement on 2026-02-19, the stock price moved by -50.55% on the day of the release. Over the subsequent five days, it saw a -48.99% change. Historically, GRAL's stock price tends to shift by an average of -7.45% in the 10 days leading up to earnings and -9.46% in the 10 days following, providing insight into potential market.

For , analysts estimate GRAL's annual revenue to reach , while the EPS is projected at . These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between GRAL's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, GRAL's stock price typically moves by -7.45% in the 10 days before its earnings and -9.46% in the 10 days after. For the upcoming earnings, analysts expect an EPS of and revenue of .

The earnings call summary presents a mixed outlook. While there is a positive emphasis on product development and strategic partnerships, the Q&A reveals concerns about trial results and FDA approval. The NHS-Galleri study's missed endpoint and lack of significant Stage III and IV cancer reduction are worrying. However, the company's optimism about future milestones and financial health, along with potential international expansion, balances the sentiment. The lack of market cap data limits the prediction's precision, but overall, the sentiment is neutral due to these mixed signals.